The content on this site is intended for healthcare professionals only
Dr Montalbán Bravo meets with ecancertv at ASH 2016 to discuss the aetiology and prognostic outlook of pure erythroid leukaemia, a subset of acute leukaemia.
He discusses the cell lineage of the disease, and describes sequencing data helping to form a greater genetic and biological understanding of PEL and its treatment choices.
Dr Montalbán Bravo also spoke with ecancer about the clinical utility of guadecitabine and azacitadine plus verinostat.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
New classification for identifying HR myeloma based on cytogenetic abnormalities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI
Multiple myeloma in a resource constrained setting
OncoAlert Round Up for August 25th - 31st, 2023
Choosing Wisely in radiology Tanzania
